Ewa M Wandzioch
age ~64
from Grand Island, NY
- Also known as:
-
- Adam Giannetti
- Ewa H
Ewa Wandzioch Phones & Addresses
- Grand Island, NY
- Glenside, PA
- Philadelphia, PA
- 7801 Linden Rd, Glenside, PA 19038
Resumes
Scientific Specialist
view sourceLocation:
640 Freedom Business Dr, King Of Prussia, PA
Industry:
Higher Education
Work:
Complete Healthcare Communications - Chadds Ford, PA since Jul 2012
Medical Writer
Venenum BioDesign, LLC - Hamilton, NJ Jun 2011 - Jul 2012
Research Scientist
University of Pennsylvania Jan 2009 - Jun 2011
RESEARCH ASSOCIATE
Fox Chase Cancer Center Sep 2005 - Jun 2009
POSTDOCTORAL FELLOW
Umea Center for Molecular Medicine Sep 1999 - Jan 2005
PhD student
Medical Writer
Venenum BioDesign, LLC - Hamilton, NJ Jun 2011 - Jul 2012
Research Scientist
University of Pennsylvania Jan 2009 - Jun 2011
RESEARCH ASSOCIATE
Fox Chase Cancer Center Sep 2005 - Jun 2009
POSTDOCTORAL FELLOW
Umea Center for Molecular Medicine Sep 1999 - Jan 2005
PhD student
Education:
Umea University 1999 - 2005
PhD, Molecular Biology Umea University 1999 - 2004
Master, Molecular Biology
PhD, Molecular Biology Umea University 1999 - 2004
Master, Molecular Biology
Skills:
Molecular Biology
Cell Biology
Cell
Biochemistry
Tissue Culture
Western Blotting
Cancer
Cancer Research
Animal Models
Stem Cells
High Throughput Screening
Science
Cell Culture
Qpcr
Oncology
Laboratory
Transfection
Drug Discovery
Immunology
Pcr
Developmental Biology
Immunofluorescence
Molecular Cloning
Biomarker Discovery
Microarray
Immunohistochemistry
Medical Writing
Hematology
Hepatology
Cell Based Assays
Cell Biology
Cell
Biochemistry
Tissue Culture
Western Blotting
Cancer
Cancer Research
Animal Models
Stem Cells
High Throughput Screening
Science
Cell Culture
Qpcr
Oncology
Laboratory
Transfection
Drug Discovery
Immunology
Pcr
Developmental Biology
Immunofluorescence
Molecular Cloning
Biomarker Discovery
Microarray
Immunohistochemistry
Medical Writing
Hematology
Hepatology
Cell Based Assays
Languages:
Swedish
Polish
Polish
Postdoc Associate At Fox Chase Cancer Center
view sourcePosition:
Postdoc associate at Fox Chase Cancer Center
Location:
Greater Philadelphia Area
Industry:
Research
Work:
Fox Chase Cancer Center
Postdoc associate
Postdoc associate
Education:
PhD
Ewa Wandzioch Wyndmoor, PA
view sourceWork:
AlphaBioCom
Aug 2013 to 2000
Scientific Communications Manager Complete Healthcare Communications
2012 to Jul 2013
MEDICAL WRITER Venenum Biodesign
Hamilton, NJ
2011 to 2012
RESEARCH SCIENTIST, TARGET BIOLOGY, CANCER SIGNALING AND CELL CYCLE University of Pennsylvania
Philadelphia, PA
Jun 2009 to Jun 2011
Research Associate Fox Chase Cancer Center
Philadelphia, PA
2005 to 2009
POSTDOCTORAL FELLOW, STEM CELL AND EPIGENETIC PROGRAM Umea University
Ume
1999 to 2005
PHD STUDENT, UMEA CENTER FOR MOLECULAR MEDICINE Umea University
Ume
1997 to 1999
Rotation student, Department of Neurobiology and Oncology AlphaBioCom
Medical writer
Aug 2013 to 2000
Scientific Communications Manager Complete Healthcare Communications
2012 to Jul 2013
MEDICAL WRITER Venenum Biodesign
Hamilton, NJ
2011 to 2012
RESEARCH SCIENTIST, TARGET BIOLOGY, CANCER SIGNALING AND CELL CYCLE University of Pennsylvania
Philadelphia, PA
Jun 2009 to Jun 2011
Research Associate Fox Chase Cancer Center
Philadelphia, PA
2005 to 2009
POSTDOCTORAL FELLOW, STEM CELL AND EPIGENETIC PROGRAM Umea University
Ume
1999 to 2005
PHD STUDENT, UMEA CENTER FOR MOLECULAR MEDICINE Umea University
Ume
1997 to 1999
Rotation student, Department of Neurobiology and Oncology AlphaBioCom
Medical writer
Education:
FOX CHASE CANCER CENTER -
Philadelphia, PA
2005 to 2009
Postdoctoral studies in in Stem Cell Biology and Epigenetics UMEA UNIVERSITY, Umea Center for Molecular Medicine
Ume
1999 to 2004
PhD in Molecular Biology UMEA UNIVERSITY, Depatment of Oncology
Ume
1997 to 1998
Master in Molecular Biology/Oncology
Philadelphia, PA
2005 to 2009
Postdoctoral studies in in Stem Cell Biology and Epigenetics UMEA UNIVERSITY, Umea Center for Molecular Medicine
Ume
1999 to 2004
PhD in Molecular Biology UMEA UNIVERSITY, Depatment of Oncology
Ume
1997 to 1998
Master in Molecular Biology/Oncology
Ewa Wandzioch Wyndmoor, PA
view sourceWork:
Venenum Biodesign
2011 to 2000
RESEARCH SCIENTIST, TARGET BIOLOGY, CANCER SIGNALING AND CELL CYCLE University of Pennsylavnia
Philadelphia, PA
2009 to 2011
Research Associate Fox Chase Cancer Center
Philadelphia, PA
2005 to 2009
Postdoctoral Fellow
2011 to 2000
RESEARCH SCIENTIST, TARGET BIOLOGY, CANCER SIGNALING AND CELL CYCLE University of Pennsylavnia
Philadelphia, PA
2009 to 2011
Research Associate Fox Chase Cancer Center
Philadelphia, PA
2005 to 2009
Postdoctoral Fellow
Education:
University of Pennsylvania
Philadelphia, PA
Jan 2009 to Jan 2011
Post-doctoctoral in Cell and Developmental Biology Umea University
Ume
Jan 1999 to Jan 2004
Ph.D. in Molecular Biology, Stem Cell Biology, Hematology, Hepatology UMEA UNIVERSITY, Umea, Sweden
Jan 1997
Master in Molecular Biology, Cancer Biology
Philadelphia, PA
Jan 2009 to Jan 2011
Post-doctoctoral in Cell and Developmental Biology Umea University
Ume
Jan 1999 to Jan 2004
Ph.D. in Molecular Biology, Stem Cell Biology, Hematology, Hepatology UMEA UNIVERSITY, Umea, Sweden
Jan 1997
Master in Molecular Biology, Cancer Biology
Skills:
Molecular Biology, Stem Cell Biology, Cancer Biology, Biochemistry, Developmental Biology, Mice, Science writing and editing
Us Patents
-
Pme-1 As A Biomarker To Predict And Diagnose An Increased Risk Of Endometrial Cancer And Gene Silencing Of Pme-1 To Inhibit Epithelial To Mesenchymal Transition
view source -
US Patent:20170226520, Aug 10, 2017
-
Filed:Apr 14, 2017
-
Appl. No.:15/487548
-
Inventors:- Hamilton NJ, US
Michelle Pusey - Bordentown NJ, US
Ewa Wandzioch - Wyndmoor PA, US
Sophie Marie Genevieve Bail - Princeton NJ, US
Amy Lynn Wenda - North Brunswick NJ, US -
Assignee:Medical Diagnostic Laboratories, L.L.C. - Hamilton NJ
-
International Classification:C12N 15/113
C12Q 1/68 -
Abstract:Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
-
Pme-1 As A Biomarker To Predict And Diagnose An Increased Risk Of Endometrial Cancer And Gene Silencing Of Pme-1 To Inhibit Epithelial To Mesenchymal Transition
view source -
US Patent:20140323546, Oct 30, 2014
-
Filed:Apr 28, 2014
-
Appl. No.:14/263085
-
Inventors:Lyndi Rice - Philadelphia PA, US
Michelle Pusey - Bordentown NJ, US
Ewa Wandzioch - Wyndmoor PA, US -
Assignee:MEDICAL DIAGNOSTIC LABORATORIES, LLC - Hamilton NJ
-
International Classification:C12Q 1/68
G01N 33/574
C12N 15/113 -
US Classification:514 44 A, 435 71, 435 792, 435 612, 435375
-
Abstract:Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
Youtube
Get Report for Ewa M Wandzioch from Grand Island, NY, age ~64